About Us

Radiation Barrier is an adaptive Immunotherapy company that measures and activates genetic cellular repair with direct applications to cancer, inflammatory and autoimmune diseases.

The Humanity Behind the Science, How it All Began…

After watching his wife suffer needlessly during her valiant battle with cancer, Dr. Blankenbecler began to ponder how he could turn the tragic loss of his wife into something positive.  As a Professor of Theoretical Particle Physics and the head of the Stanford University Linear Nuclear Accelerator, Dr. Blankenbecler had a great deal of experience in solving theoretical problems.

Now it was personal.

He turned to biophysics and began by studying protein structures.  His discoveries while at Stanford resulted in a patented method for quicker computer comparisons of protein structures.  This patent is now widely used by major pharmaceutical companies to develop and more quickly launch promising pharmaceutical drugs.

Yet, Dr. Blankenbecler’s mission to significantly reduce cancer treatment side effects and improve outcomes was not yet complete.

After attending a lecture on the after-effects of nuclear testing, where the speaker documented strange cases in which low-dose radiation seemed to be beneficial, Dr. Blankenbecler’s interest was piqued.   How could this be?  From simple physics arguments, he knew that radiation breaks chemical bonds and therefore should be harmful. Also, if low dose radiation was sometimes beneficial, how come it wasn’t used in medical therapy?

Like many other things in his problem-solving career, the answer was “outside the box.”  The Department of Energy and other researchers were studying the effects of radiation exposure for radiation worker protection.  However, no one was researching the potential positive effects of low-dose radiation from a medical therapy perspective.

After a long search and study of the scientific literature, collaboration with the Nevada Cancer Institute and engineers for a pre-eminent Linear Nuclear Accelerator manufacturer, he was able to prove his thesis, and a new therapy protocol arose; CARE (Cellular Adaptive Response Effect) Pre-Dose Therapy™.

Working with Professor John Robertson of Virginia Tech, he completed a pre-clinical validation and published his results in a peer-reviewed journal.  A series of well-received seminars on the beneficial effects of low-dose therapy for Oncologist, Radiologists, Physicists, and doctors were given at Stanford University, Brown University, RI Cancer Institute, VA Tech, Wake Forest University Hospital (NC), among others.  Based on the positive reception to the protocol and on the advice of his physician colleagues at Stanford University, Dr. Blankenbecler patented the CARE Pre-Dose Therapy protocol.

In 2015, Radiation Barrier was formed to commercialize Dr. Blankenbecler’s discoveries and patents.  A strong team of executives, who also have been touched by cancer, have joined Dr. Blankenbecler to bring a multitude of products  to market, delivering the best outcomes for cancer, inflammatory and autoimmune diseases.

The C.A.R.E. RadioImmunotherapy clinical protocol was developed by Dr. Blankenbecler working with a team of leading cancer researchers and doctors in a world-renown FDA, Kyoto, and Helsinki research compliant hospital.  The first-ever C.A.R.E. RadioImmunotherapy clinical trials in humans is underway and will provide the world’s largest and most valuable database of this type of data in existance.

Combining DNA damage and repair activation with immuno-oncology agents unlocks additional efficacy gains.

—  CEO, International Pharmaceuticals company

Recent Articles

Oriana Sousa, 28, who lives in Marinha Grande, Portugal, had a rare, aggressive form of ovarian cancer. Traditional trea...
The science of using immunotherapy to treat cancer is advancing rapidly, marked by the National Cancer Institute’s rec...
The science of using immunotherapy to treat cancer is advancing rapidly, marked by the National Cancer Institute’s rec...
A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why...